{"id":8067,"date":"2025-07-23T10:34:21","date_gmt":"2025-07-23T07:34:21","guid":{"rendered":"https:\/\/jordan-cardiac.org\/?p=8067"},"modified":"2025-07-23T10:34:21","modified_gmt":"2025-07-23T07:34:21","slug":"event-esc-heart-failure-congress-2025","status":"publish","type":"post","link":"https:\/\/jordan-cardiac.org\/en\/event-esc-heart-failure-congress-2025\/","title":{"rendered":"Event: ESC Heart Failure Congress 2025"},"content":{"rendered":"

Event: ESC Heart Failure Congress 2025<\/span><\/p>\n

Presenter: Dr. Marianna Fontana (London, UK)<\/span><\/p>\n

Source: ESC Heart Failure News + J Am Coll Cardiol<\/span><\/p>\n

1. Background:<\/span>
\n\u2022 ATTR-CM (transthyretin-mediated amyloid cardiomyopathy) is a life-threatening heart condition caused by abnormal TTR protein deposition in the heart muscle.<\/span>
\n\u2022 Vutrisiran is a subcutaneous RNAi therapy that inhibits TTR production.<\/span><\/p>\n

2. Study Design:<\/span>
\n\u2022 HELIOS-B was a phase 3, double-blind, placebo-controlled, international RCT.<\/span>
\n\u2022 Included 654 ATTR-CM patients, randomized to:<\/span>
\n\u2022 Vutrisiran 25 mg SC every 3 months<\/span>
\n\u2022 Placebo<\/span>
\n\u2022 Duration: Up to 36 months, followed by an open-label extension (OLE) to 42 months.<\/span>
\n\u2022 Tafamidis use was permitted before or during the trial.<\/span><\/p>\n

3. Endpoints Evaluated:<\/span>
\n\u2022 All-cause mortality and CV death (up to 42 months)<\/span>
\n\u2022 Recurrent CV events, HF hospitalizations, and urgent HF visits (up to 36 months)<\/span><\/p>\n

4. Main Results:<\/span>
\n1. Mortality Reduction at 42 Months:<\/span>
\n\u2022 All-cause mortality: HR 0.64 (95% CI: 0.46\u20130.88; P=0.007)<\/span>
\n\u2022 CV mortality: HR 0.67 (95% CI: 0.47\u20130.96; P=0.038)<\/span>
\n2. CV Event Reductions at 36 Months:<\/span>
\n\u2022 Recurrent CV events: RR 0.73 (P<0.001)<\/span>
\n\u2022 CV hospitalizations: RR 0.75 (P=0.004)<\/span>
\n\u2022 Urgent HF visits: RR 0.54 (P=0.041)<\/span>
\n\u2022 HF hospitalizations: RR 0.67 (P=0.002)<\/span>
\n3. Subgroup Analyses showed consistent results across age, NYHA class, ATTR type, and NT-proBNP levels.<\/span><\/p>\n

5. Conclusion:<\/span>
\n\u2022 Vutrisiran significantly reduced mortality and CV events in patients with ATTR-CM.<\/span>
\n\u2022 Benefits were observed with or without tafamidis use.<\/span>
\n\u2022 These findings reinforce the primary results of HELIOS-B and support the use of vutrisiran as a disease-modifying treatment for ATTR-CM.<\/span>
\n6. ESC Heart Failure 2025 \u2013 The treatment landscape for ATTR-CM is rapidly evolving, with different drugs targeting different aspects of the pathophysiology. Vincenzo Castiglione presents findings from a network meta-analysis, which evaluated the relative efficacy of four disease-modifying treatments for ATTR-CM: tafamidis, acoramidis, patisiran, and vutrisiran.<\/span>
\nHELIOS-B Trial \u2013 Vutrisiran in ATTR-CM<\/span>
\nSimultaneous Publication:<\/span>
\nThe full study was published concurrently in the Journal of the American College of Cardiology (JACC).<\/span><\/p>\n

Published: May 22, 2025<\/span>
\n\"\ud83d\udd17\"\u00a0JACC \u2013 HELIOS-B Publication<\/span>
\nhttps:\/\/www.escardio.org\/Congresses\/ESC-Heart-Failure\/Congress-news\/<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Event: ESC Heart Failure Congress 2025 Presenter: Dr. Marianna Fontana (London, UK) Source: ESC Heart Failure News + J Am Coll Cardiol 1. Background: \u2022 ATTR-CM (transthyretin-mediated amyloid cardiomyopathy) is a life-threatening heart condition caused by abnormal TTR protein deposition in the heart muscle. \u2022 Vutrisiran is a subcutaneous RNAi therapy that inhibits TTR production. […]<\/p>\n","protected":false},"author":145,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-8067","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/8067","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/users\/145"}],"replies":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/comments?post=8067"}],"version-history":[{"count":1,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/8067\/revisions"}],"predecessor-version":[{"id":8068,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/8067\/revisions\/8068"}],"wp:attachment":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/media?parent=8067"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/categories?post=8067"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/tags?post=8067"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}